Daniel S. Quintana

Daniel S. Quintana

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Daniel S. Quintana

Department of Psychology, University of Oslo, Oslo, Norway

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2010 in Biological Psychiatry
Verified
Journal Article
Closed access
AKAndrew Haddon Kemp
Andrew Haddon Kemp
DQDaniel S. Quintana
Daniel S. Quintana
MGMarcus A. Gray
Marcus A. Gray
KFKim L. Felmingham
Kim L. Felmingham
KBKerri Brown
Kerri Brown
JGJustine M. Gatt
Justine M. Gatt

11 July 2014 in Frontiers in Psychiatry
Verified
Journal Article
Open access
PDF file
JCJohn A. Chalmers
John A. Chalmers
DQDaniel S. Quintana
Daniel S. Quintana
MAMaree J.-Anne Abbott
Maree J.-Anne Abbott
AKAndrew Haddon Kemp
Andrew Haddon Kemp
Background: Anxiety disorders increase risk of future cardiovascular disease (CVD) and mortality, even after controlling for confounds including smoking, lifestyle, and socioeconomic status, and irrespective of a history of medical disorders. While impaired vagal function, indicated by reductions in heart rate variability (HRV), may be one mechanism linking anxiety disorders to CVD, prior studies have reported inconsistent findings highlighting the need for meta-analysis. Method: Studies comparing resting state HRV recordings in patients with an anxiety disorder as a primary diagnosis and healthy controls were considered for meta-analysis. Results: Meta-analyses were based on 36 articles, including 2086 patients with an anxiety disorder and 2294 controls. Overall, anxiety disorders were characterised by lower HRV (high frequency: Hedges’ g = -.29. 95%CI: -.41 to -.17, p < 0.001; time domain: Hedges’ g = -0.45, 95%CI: -0.57 to -0.33, p < .001) than controls. Panic Disorder (n=447), Post-Traumatic Stress Disorder (n=192), Generalized Anxiety Disorder (n=68), and Social anxiety disorder (n=90), but not Obsessive Compulsive Disorder (n=40), displayed reductions in high frequency HRV relative to controls (all ps < .001). Conclusions: Anxiety disorders are associated with reduced HRV, findings associated with a small to moderate effect size. Findings have important implications for future physical health and wellbeing of patients, highlighting a need for comprehensive cardiovascular risk reduction.

25 April 2017 in Molecular Psychiatry
Verified
Journal Article
Open access
EDE A Demetriou
E A Demetriou
ALA Lampit
A Lampit
DQD S Quintana
D S Quintana
SNS L Naismith
S L Naismith
YSY J C Song
Y J C Song
Adam GuastellaAdam Guastella
Adam Guastella
Evidence of executive dysfunction in autism spectrum disorders (ASD) across development remains mixed and establishing its role is critical for guiding diagnosis and intervention. The primary objectives of this meta-analysis is to analyse executive function (EF) performance in ASD, the fractionation across EF subdomains, the clinical utility of EF measures and the influence of multiple moderators (for example, age, gender, diagnosis, measure characteristics). The Embase, Medline and PsychINFO databases were searched to identify peer-reviewed studies published since the inclusion of Autism in DSM-III (1980) up to end of June 2016 that compared EF in ASD with neurotypical controls. A random-effects model was used and moderators were tested using subgroup analysis. The primary outcome measure was Hedges' g effect size for EF and moderator factors. Clinical sensitivity was determined by the overlap percentage statistic (OL%). Results were reported according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. A total of 235 studies comprising 14 081 participants were included (N, ASD=6816, Control=7265). A moderate overall effect size for reduced EF (Hedges' g=0.48, 95% confidence interval (CI) 0.43-0.53) was found with similar effect sizes across each domain. The majority of moderator comparisons were not significant although the overall effect of executive dysfunction has gradually reduced since the introduction of ASD. Only a small number of EF measures achieved clinical sensitivity. This study confirms a broad executive dysfunction in ASD that is relatively stable across development. The fractionation of executive dysfunction into individual subdomains was not supported, nor was diagnostic sensitivity. Development of feasible EF measures focussing on clinical sensitivity for diagnosis and treatment studies should be a priority.

17 May 2021 in Nature Human Behaviour
Verified
Journal Article
Closed access
PDF file
DPDouglas A. Parry
Douglas A. Parry
BDBrittany I. Davidson
Brittany I. Davidson
CSCraig J. R. Sewall
Craig J. R. Sewall
JFJacob T. Fisher
Jacob T. Fisher
HMHannah Mieczkowski
Hannah Mieczkowski
DQDaniel S. Quintana
Daniel S. Quintana

1 September 2013 in International Journal of Psychophysiology
Verified
Journal Article
Closed access
AKAndrew Haddon Kemp
Andrew Haddon Kemp
DQDaniel S. Quintana
Daniel S. Quintana

1 March 2016 in Journal of Psychiatry and Neuroscience
Verified
Journal Article
Closed access
GAGail A. Alvares
Gail A. Alvares
DQDaniel S. Quintana
Daniel S. Quintana
IHIan B. Hickie
Ian B. Hickie
Adam GuastellaAdam Guastella
Adam Guastella
Background: Autonomic nervous system (ANS) dysfunction is a putative underlying mechanism for increased cardiovascular disease risk in individuals with psychiatric disorders. Previous studies suggest that this risk may be related to psychotropic medication use. In the present study we systematically reviewed and analyzed published studies of heart rate variability (HRV), measuring ANS output, to determine the effect of psychiatric illness and medication use. Methods: We searched for studies comparing HRV in physically healthy adults with a diagnosed psychiatric disorder to controls and comparing HRV pre- and post-treatment with a psychotropic medication. Results: In total, 140 case–control (mood, anxiety, psychosis, dependent disorders, k = 151) and 30 treatment (antidepressants, antipsychotics; k = 43) studies were included. We found that HRV was reduced in all patient groups compared to controls (Hedges g = −0.583) with a large effect for psychotic disorders (Hedges g = −0.948). Effect sizes remained highly significant for medication-free patients compared to controls across all disorders. Smaller and significant reductions in HRV were observed for specific antidepressants and antipsychotics. Limitations: Study quality significantly moderated effect sizes in case–control analyses, underscoring the importance of assessing methodological quality when interpreting HRV findings. Conclusion: Combined findings confirm substantial reductions in HRV across psychiatric disorders, and these effects remained significant even in medication-free individuals. Reductions in HRV may therefore represent a significant mechanism contributing to elevated cardiovascular risk in individuals with psychiatric disorders. The negative impact of specific medications on HRV suggest increased risk for cardiovascular disease in these groups, highlighting a need for treatment providers to consider modifiable cardiovascular risk factors to attenuate this risk.